- Ticker
- ADXN
- Price
- 1.25
- Stock movement up
- +0.09 (7.76%)
- Company name
- Addex Therapeutics Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 24.03M
- Ent værdi
- 17.90M
- Pris/omsætning
- 19.58
- Pris/bog
- 3.02
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -
- 1 års afkast
- -78.19%
- 3 års afkast
- -
- 5 års afkast
- -
- 10 års afkast
- -
Senest opdateret: 2023-02-02
UDBYTTE
ADXN betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 19.58 |
| Pris til egenkapital | 3.02 |
| EV i forhold til salg | 14.58 |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 19.22M |
| EPS (TTM) | -2.71 |
| FCF pr. aktie (TTM) | -2.05 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 1.23M |
| Bruttofortjeneste (TTM) | 0.00 |
| Driftsindkomst (TTM) | -21.30M |
| Nettoindkomst (TTM) | -21.58M |
| EPS (TTM) | -2.71 |
| EPS (1 år frem) | - |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | - |
| Driftsmargin (TTM) | -1735.01% |
| Fortjenstmargin (TTM) | -1757.77% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 10.42M |
| Nettotilgodehavender | 457.04K |
| Omsætningsaktiver i alt | 11.70M |
| Goodwill | 0.00 |
| Immaterielle aktiver | 0.00 |
| Ejendomme, anlæg og udstyr | 0.00 |
| Sum aktiver | 12.24M |
| Kreditor | 2.99M |
| Kortfristet/nuværende langsigtet gæld | 447.11K |
| Summen af kortfristede forpligtelser | 4.13M |
| Sum gæld | 4.29M |
| Aktionærernes egenkapital | 7.95M |
| Materielle nettoaktiver | 7.95M |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | -16.31M |
| Investeringsudgifter (TTM) | 26.23K |
| Fri pengestrøm (TTM) | -16.34M |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | -271.34% |
| Afkast af aktiver | -176.26% |
| Afkast af investeret kapital | -261.93% |
| Kontant afkast af investeret kapital | -198.31% |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 1.20 |
| Daglig høj | 1.35 |
| Daglig lav | 1.20 |
| Daglig volumen | 494K |
| Højeste gennem alle tider | 24.19 |
| 1 års analytiker estimat | - |
| Beta | 1.52 |
| EPS (TTM) | -2.71 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 2 May 2023 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ADXN | S&P500 | |
| Nuværende prisfald fra top notering | -94.83% | -12.75% |
| Højeste prisfald | -97.71% | -56.47% |
| Højeste efterår dato | 22 Dec 2022 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -66.33% | -11.49% |
| Gennemsnitlig tid til nyt højdepunkt | 232 days | 13 days |
| Maks. tid til nyt højdepunkt | 530 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
24.03M
Markedsværdi kategori
Small-cap
Beskrivelse
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot"Marie"Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Personale
26
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Timothy Dyer
Land
USA
By
Geneva
Aktietype
American depositary share
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 19, 2023 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modul...
19. januar 2023
Addex to receive USD 1 million in additional research fundingCollaboration continues to advance through drug candidate selection phase Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, D...
8. december 2022
CHF10.4M ($10.4M) of cash and cash equivalents at September 30, 2022Janssen led ADX71149 Phase 2 study in epilepsy on track to complete part 1 in Q1 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Gen...
11. november 2022
Geneva, Switzerland, November 3, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today ...
3. november 2022
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 3, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modula...
3. november 2022
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 1, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modula...
1. november 2022
Geneva, Switzerland, September 20, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, anno...
20. september 2022
CHF8.8M ($9.3M) of cash and cash equivalents at June 30, 2022CHF4.6M equity financing in July extends cash runway into Q2 2023Janssen led ADX71149 Phase 2 study in epilepsy expected to report data in ...
18. august 2022
Addex to Receive CHF850,000 ($900,000) of Additional Funding; Addex’s Reserved Indications Expanded to include Chronic Cough Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 15, ...
15. august 2022
Geneva, Switzerland, August 12, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today a...
12. august 2022
Næste side